{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T10:06:07Z","timestamp":1750327567796,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00228-022-03313-2","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T06:02:19Z","timestamp":1650520939000},"page":"955-963","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Influence of daily versus alternate-day dosing of vonoprazan on intragastric pH, serum gastrin, and the antiplatelet function of clopidogrel"],"prefix":"10.1007","volume":"78","author":[{"given":"Tomohiro","family":"Higuchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihoko","family":"Yamade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Tani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Kagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Uotani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Hamaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moriya","family":"Iwaizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Osawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2202-595X","authenticated-orcid":false,"given":"Takahisa","family":"Furuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,20]]},"reference":[{"key":"3313_CR1","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1136\/svn-2019-000314","volume":"5","author":"W Du","year":"2020","unstructured":"Du W, Zhao X, Wang Y et al (2020) Gastrointestinal bleeding during acute ischaemic stroke hospitalisation increases the risk of stroke recurrence. Stroke Vasc Neurol 5:116\u2013120","journal-title":"Stroke Vasc Neurol"},{"key":"3313_CR2","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.jacc.2009.07.019","volume":"54","author":"E Nikolsky","year":"2009","unstructured":"Nikolsky E, Stone GW, Kirtane AJ et al (2009) Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol 54:1293\u20131302","journal-title":"J Am Coll Cardiol"},{"key":"3313_CR3","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1007\/s00380-021-01822-1","volume":"36","author":"S Sakai","year":"2021","unstructured":"Sakai S, Tara S, Yamamoto T et al (2021) Gastrointestinal bleeding increases the risk of subsequent cardiovascular events in patients with acute cardiovascular diseases requiring intensive care. Heart Vessels 36:1327\u20131335","journal-title":"Heart Vessels"},{"key":"3313_CR4","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1177\/1074248410369109","volume":"15","author":"M Tran","year":"2010","unstructured":"Tran M, Tafreshi J, Pai RG (2010) Review article: combination of clopidogrel and proton pump inhibitors: implications for clinicians. J Cardiovasc Pharmacol Ther 15:326\u2013337","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"3313_CR5","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s11239-016-1460-2","volume":"43","author":"T Furuta","year":"2017","unstructured":"Furuta T, Sugimoto M, Kodaira C et al (2017) Influence of low-dose proton pump inhibitors administered concomitantly or separately on the anti-platelet function of clopidogrel. J Thromb Thrombolysis 43:333\u2013342","journal-title":"J Thromb Thrombolysis"},{"key":"3313_CR6","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1001\/jama.2015.13766","volume":"314","author":"ED Kantor","year":"2015","unstructured":"Kantor ED, Rehm CD, Haas JS et al (2015) Trends in Prescription Drug Use Among Adults in the United States From 1999\u20132012. JAMA 314:1818\u20131830","journal-title":"JAMA"},{"key":"3313_CR7","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1159\/000456072","volume":"95","author":"S Hoshino","year":"2017","unstructured":"Hoshino S, Kawami N, Takenouchi N et al (2017) Efficacy of Vonoprazan for Proton Pump Inhibitor-Resistant Reflux Esophagitis. Digestion 95:156\u2013161","journal-title":"Digestion"},{"key":"3313_CR8","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/apt.13325","volume":"42","author":"Y Sakurai","year":"2015","unstructured":"Sakurai Y, Mori Y, Okamoto H et al (2015) Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects\u2013a randomised open-label cross-over study. Aliment Pharmacol Ther 42:719\u2013730","journal-title":"Aliment Pharmacol Ther"},{"key":"3313_CR9","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/apt.15641","volume":"51","author":"T Takeuchi","year":"2020","unstructured":"Takeuchi T, Furuta T, Fujiwara Y et al (2020) Randomised trial of acid inhibition by vonoprazan 10\/20 mg once daily vs rabeprazole 10\/20 mg twice daily in healthy Japanese volunteers (SAMURAI pH study). Aliment Pharmacol Ther 51:534\u2013543","journal-title":"Aliment Pharmacol Ther"},{"key":"3313_CR10","doi-asserted-by":"crossref","unstructured":"Gotoh Y, Ishibashi E, Honda S et al (2020) Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease. Medicine (Baltimore) 99:e195200","DOI":"10.1097\/MD.0000000000019520"},{"key":"3313_CR11","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.3748\/wjg.v24.i14.1550","volume":"24","author":"K Ashida","year":"2018","unstructured":"Ashida K, Iwakiri K, Hiramatsu N et al (2018) Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole. World J Gastroenterol 24:1550\u20131561","journal-title":"World J Gastroenterol"},{"key":"3313_CR12","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1136\/gutjnl-2017-314852","volume":"67","author":"T Kawai","year":"2018","unstructured":"Kawai T, Oda K, Funao N et al (2018) Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. Gut 67:1033\u20131041","journal-title":"Gut"},{"key":"3313_CR13","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1136\/gutjnl-2017-314010","volume":"67","author":"Y Mizokami","year":"2018","unstructured":"Mizokami Y, Oda K, Funao N et al (2018) Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. Gut 67:1042\u20131051","journal-title":"Gut"},{"key":"3313_CR14","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40262-015-0326-7","volume":"55","author":"EH The","year":"2016","unstructured":"The EH, Blocker F-i-C-C, Fumarate V (2016) Pharmacokinetic and Pharmacodynamic Considerations. Clin Pharmacokinet 55:409\u2013418","journal-title":"Clin Pharmacokinet"},{"key":"3313_CR15","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/cpt.863","volume":"103","author":"T Kagami","year":"2018","unstructured":"Kagami T, Yamade M, Suzuki T et al (2018) Comparative Study of Effects of Vonoprazan and Esomeprazole on Antiplatelet Function of Clopidogrel or Prasugrel in Relation to CYP2C19 Genotype. Clin Pharmacol Ther 103:906\u2013913","journal-title":"Clin Pharmacol Ther"},{"key":"3313_CR16","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1111\/bcp.13914","volume":"85","author":"R Funakoshi","year":"2019","unstructured":"Funakoshi R, Tomoda Y, Kudo T et al (2019) Effects of proton pump inhibitors, esomeprazole and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, in healthy volunteers. Br J Clin Pharmacol 85:1454\u20131463","journal-title":"Br J Clin Pharmacol"},{"key":"3313_CR17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3389\/fphar.2020.00053","volume":"11","author":"Y Wang","year":"2020","unstructured":"Wang Y, Wang C, Wang S et al (2020) Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo. Front Pharmacol 11:53","journal-title":"Front Pharmacol"},{"key":"3313_CR18","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1007\/s12325-016-0345-2","volume":"33","author":"K Otake","year":"2016","unstructured":"Otake K, Sakurai Y, Nishida H et al (2016) Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438). Adv Ther 33:1140\u20131157","journal-title":"Adv Ther"},{"key":"3313_CR19","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/apt.15062","volume":"49","author":"T Oshima","year":"2019","unstructured":"Oshima T, Arai E, Taki M et al (2019) Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis. Aliment Pharmacol Ther 49:140\u2013146","journal-title":"Aliment Pharmacol Ther"},{"key":"3313_CR20","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3164\/jcbn.17-128","volume":"63","author":"K Ohkuma","year":"2018","unstructured":"Ohkuma K, Iida H, Inoh Y et al (2018) Comparison of the early effects of vonoprazan, lansoprazole and famotidine on intragastric pH: a three-way crossover study. J Clin Biochem Nutr 63:80\u201383","journal-title":"J Clin Biochem Nutr"},{"key":"3313_CR21","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1159\/000485795","volume":"97","author":"M Umezawa","year":"2018","unstructured":"Umezawa M, Kawami N, Hoshino S et al (2018) Efficacy of On-Demand Therapy Using 20-mg Vonoprazan for Mild Reflux Esophagitis. Digestion 97:309\u2013315","journal-title":"Digestion"},{"key":"3313_CR22","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s00228-021-03162-5","volume":"77","author":"T Suzuki","year":"2021","unstructured":"Suzuki T, Higuchi T, Kagami T et al (2021) Effects of pirenzepine on vonoprazan-induced gastric acid inhibition and hypergastrinemia. Eur J Clin Pharmacol 77:971\u2013978","journal-title":"Eur J Clin Pharmacol"},{"key":"3313_CR23","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1111\/apt.13588","volume":"43","author":"T Kagami","year":"2016","unstructured":"Kagami T, Sahara S, Ichikawa H et al (2016) Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther 43:1048\u20131059","journal-title":"Aliment Pharmacol Ther"},{"key":"3313_CR24","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1160\/TH13-01-0004","volume":"110","author":"U Baber","year":"2013","unstructured":"Baber U, Bander J, Karajgikar R et al (2013) Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity. Thromb Haemost 110:118\u2013123","journal-title":"Thromb Haemost"},{"key":"3313_CR25","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1111\/bcp.14296","volume":"86","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhu X, Zhan Y et al (2020) Impacts of CYP2C19 genetic polymorphisms on bioavailability and effect on platelet adhesion of vicagrel, a novel thienopyridine P2Y(12) inhibitor. Br J Clin Pharmacol 86:1860\u20131874","journal-title":"Br J Clin Pharmacol"},{"key":"3313_CR26","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1046\/j.1365-2168.1998.00687.x","volume":"85","author":"KG Pursnani","year":"1998","unstructured":"Pursnani KG, Mohiuddin MA, Geisinger KR et al (1998) Experimental study of acid burden and acute oesophagitis. Br J Surg 85:677\u2013680","journal-title":"Br J Surg"},{"key":"3313_CR27","doi-asserted-by":"crossref","unstructured":"Hatlebakk JG (2003) Review article: gastric acidity--comparison of esomeprazole with other proton pump inhibitors. Aliment Pharmacol Ther 17 Suppl 1:10\u20135; discussion 16\u20137","DOI":"10.1046\/j.1365-2036.17.s1.3.x"},{"key":"3313_CR28","doi-asserted-by":"crossref","unstructured":"Armstrong D (2004) Review article: gastric pH -- the most relevant predictor of benefit in reflux disease? Aliment Pharmacol Ther 20 Suppl 5:19\u201326; discussion 38\u20139.","DOI":"10.1111\/j.1365-2036.2004.02140.x"},{"key":"3313_CR29","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/bcpt.13023","volume":"123","author":"PF Haastrup","year":"2018","unstructured":"Haastrup PF, Thompson W, S\u00f8ndergaard J et al (2018) Side Effects of Long-Term Proton Pump Inhibitor Use: A Review. Basic Clin Pharmacol Toxicol 123:114\u2013121","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"3313_CR30","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1002\/cpt.2015","volume":"109","author":"JJ Lima","year":"2021","unstructured":"Lima JJ, Thomas CD, Barbarino J et al (2021) Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther 109:1417\u20131423","journal-title":"Clin Pharmacol Ther"},{"key":"3313_CR31","doi-asserted-by":"crossref","unstructured":"Sugano K (2018) Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. Therap Adv Gastroenterol 11:1756283x17745776","DOI":"10.1177\/1756283X17745776"},{"key":"3313_CR32","first-page":"1","volume":"8","author":"HL Waldum","year":"2017","unstructured":"Waldum HL, Sagatun L, Mj\u00f8nes P (2017) Gastrin and Gastric Cancer Front Endocrinol (Lausanne) 8:1","journal-title":"Gastrin and Gastric Cancer Front Endocrinol (Lausanne)"},{"key":"3313_CR33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/00004836-199701000-00004","volume":"24","author":"M Tobi","year":"1997","unstructured":"Tobi M, Cats A, Maliakkal BJ et al (1997) Zollinger-Ellison syndrome, acromegaly, and colorectal neoplasia. J Clin Gastroenterol 24:21\u201324","journal-title":"J Clin Gastroenterol"},{"key":"3313_CR34","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1007\/BF01655502","volume":"12","author":"K Borch","year":"1988","unstructured":"Borch K, Kullman E, Hallhagen S et al (1988) Increased incidence of pancreatic neoplasia in pernicious anemia. World J Surg 12:866\u2013870","journal-title":"World J Surg"},{"key":"3313_CR35","first-page":"745","volume":"71","author":"AW Hsing","year":"1993","unstructured":"Hsing AW, Hansson LE, McLaughlin JK et al (1993) Pernicious anemia and subsequent cancer. A population-based cohort study Cancer 71:745\u2013750","journal-title":"A population-based cohort study Cancer"},{"key":"3313_CR36","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1365-2125.2010.03717.x","volume":"70","author":"T Furuta","year":"2010","unstructured":"Furuta T, Iwaki T, Umemura K (2010) Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Br J Clin Pharmacol 70:383\u2013392","journal-title":"Br J Clin Pharmacol"},{"key":"3313_CR37","doi-asserted-by":"crossref","unstructured":"Sakurai Y, Nishimura A, Kennedy G et al (2015) Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese\/non-Japanese Subjects. Clin Transl Gastroenterol 6:e94","DOI":"10.1038\/ctg.2015.18"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03313-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-022-03313-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03313-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T08:06:23Z","timestamp":1652515583000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-022-03313-2"}},"subtitle":["Influence of alternate-day dosing of vonoprazan"],"short-title":[],"issued":{"date-parts":[[2022,4,20]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["3313"],"URL":"https:\/\/doi.org\/10.1007\/s00228-022-03313-2","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2022,4,20]]},"assertion":[{"value":"28 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that there is no conflict of interest related to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}